Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
OtherTranslational (Animal and Human)

Synthesis and evaluation of 18F-enzalutamide, a new radioligand for PET Imaging of Androgen Receptors: A comparison with 16β-18F-fluoro-5α-dihydrotestosterone

Inês F. Antunes, Rutger Dost, Hilde D. Hoving, Aren van Waarde, Rudi A. Dierckx, Douwe F. Samplonius, Wijnand Helfrich, Philip H Elsinga, Erik F de Vries and Igle J. de Jong
Journal of Nuclear Medicine January 2021, jnumed.120.253641; DOI: https://doi.org/10.2967/jnumed.120.253641
Inês F. Antunes
1 University of Groningen, University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rutger Dost
2 University of Groningen, University Medical Center Groningen, Department of Urology;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hilde D. Hoving
2 University of Groningen, University Medical Center Groningen, Department of Urology;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aren van Waarde
1 University of Groningen, University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rudi A. Dierckx
1 University of Groningen, University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douwe F. Samplonius
3 University of Groningen, University Medical Center Groningen, Surgical Research Laboratory
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wijnand Helfrich
3 University of Groningen, University Medical Center Groningen, Surgical Research Laboratory
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip H Elsinga
1 University of Groningen, University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erik F de Vries
1 University of Groningen, University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Igle J. de Jong
2 University of Groningen, University Medical Center Groningen, Department of Urology;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Aim: 16β-18F-fluoro-5α-dihydrotestosterone (18F-FDHT) is a radiopharmaceutical that has been investigated as a diagnostic agent for the assessment of androgen receptor (AR) density in prostate cancer using positron emission tomography (PET). However, 18F-FDHT is rapidly metabolized in humans and excreted via the kidneys into the urine, which can compromise the detection of tumor lesions close to the bladder. Enzalutamide is an AR signaling inhibitor currently used in different stages of prostate cancer. Enzalutamide and its primary metabolite N-desmethylenzalutamide have a comparable affinity for the AR as FDHT but are both mainly excreted via the hepatic route. Radiolabeled enzalutamide could thus be a suitable candidate PET tracer for AR imaging. Here we describe the radiolabeling of enzalutamide with fluorine-18. Moreover, the in-vitro and in-vivo behavior of 18F-enzalutamide was evaluated and compared to the current standard 18F-FDHT. Methods:18F-enzalutamide was obtained by the fluorination of this nitro precursor. In-vitro cellular uptake studies with 18F-enzalutamide and 18F-FDHT were performed in LNCaP (AR+) and HEK293 (AR-) cells. Competition assays with both tracers were conducted in the LNCaP (AR+) cell line. In-vivo PET imaging, ex-vivo biodistribution, and metabolite studies with 18F-enzalutamide and 18F-FDHT were conducted in athymic nude male mice bearing an LNCaP xenograft in the shoulder. Results: 18F-enzalutamide was obtained in 1.4±0.9% radiochemical yield with an apparent molar activity of 6.2±10.3 GBq/µmol. 18F-FDHT was obtained in 1.5±0.8% yield with a molar activity > 25 GBq/µmol. Co-incubation with an excess of DHT or enzalutamide significantly reduced the cellular uptake of 18F-enzalutamide and 18F-FDHT to about 50% in AR+ LNCaP cells, but not in AR- HEK293 cells. PET and biodistribution studies in male mice bearing a LnCaP xenograft showed about 3 times higher tumor uptake for 18F-enzalutamide than for 18F-FDHT. Sixty minutes after tracer injection, 93% of 18F-enzalutamide in plasma was still intact, compared to only 3% for 18F-FDHT. Conclusion: Despite its lower apparent molar activity, 18F-enzalutamide shows higher tumor uptake and better metabolic stability than 18F-FDHT and thus seems to have more favorable properties for imaging of AR with PET. However, further evaluation in other oncological animal models and patients is still warranted to confirm these results.

  • Animal Imaging
  • Oncology: Endocrine
  • Radiopharmaceuticals
  • Androgen receptors
  • Enzalutamide
  • Mice
  • PET imaging
  • Prostate cancer
  • Copyright © 2021 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (3)
Journal of Nuclear Medicine
Vol. 62, Issue 3
March 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Synthesis and evaluation of 18F-enzalutamide, a new radioligand for PET Imaging of Androgen Receptors: A comparison with 16β-18F-fluoro-5α-dihydrotestosterone
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Synthesis and evaluation of 18F-enzalutamide, a new radioligand for PET Imaging of Androgen Receptors: A comparison with 16β-18F-fluoro-5α-dihydrotestosterone
Inês F. Antunes, Rutger Dost, Hilde D. Hoving, Aren van Waarde, Rudi A. Dierckx, Douwe F. Samplonius, Wijnand Helfrich, Philip H Elsinga, Erik F de Vries, Igle J. de Jong
Journal of Nuclear Medicine Jan 2021, jnumed.120.253641; DOI: 10.2967/jnumed.120.253641

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Synthesis and evaluation of 18F-enzalutamide, a new radioligand for PET Imaging of Androgen Receptors: A comparison with 16β-18F-fluoro-5α-dihydrotestosterone
Inês F. Antunes, Rutger Dost, Hilde D. Hoving, Aren van Waarde, Rudi A. Dierckx, Douwe F. Samplonius, Wijnand Helfrich, Philip H Elsinga, Erik F de Vries, Igle J. de Jong
Journal of Nuclear Medicine Jan 2021, jnumed.120.253641; DOI: 10.2967/jnumed.120.253641
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Translational (Animal and Human)

  • Poly(ADP-ribose)polymerase1: A potential molecular marker to identify cancer during colposcopy procedures.
  • Quantification of macrophage-driven inflammation during myocardial infarction with 18F-LW223, a novel TSPO radiotracer with binding independent of the rs6971 human polymorphism
Show more Translational (Animal and Human)

Basic (Molecular Imaging: Animal Imaging)

  • Dopamine D1 Receptor Agonist PET Tracer Development: Assessment in Non-Human Primates
  • Imaging calreticulin for early detection of immunogenic cell death during anticancer treatment
Show more Basic (Molecular Imaging: Animal Imaging)

Similar Articles

Keywords

  • Animal Imaging
  • Oncology: Endocrine
  • radiopharmaceuticals
  • Androgen receptors
  • Enzalutamide
  • Mice
  • PET imaging
  • prostate cancer
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire